Indivior PLC (LON:INDV – Get Free Report) shares fell 15.7% during mid-day trading on Thursday . The company traded as low as GBX 548.71 ($6.93) and last traded at GBX 732 ($9.25). 1,888,371 shares traded hands during trading, an increase of 166% from the average session volume of 709,477 shares. The stock had previously closed at GBX 868 ($10.97).
Analysts Set New Price Targets
Separately, Jefferies Financial Group reiterated a “buy” rating and set a GBX 1,800 ($22.74) price objective on shares of Indivior in a research note on Tuesday, December 17th.
Read Our Latest Stock Analysis on INDV
Indivior Price Performance
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- What is a Secondary Public Offering? What Investors Need to Know
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- 5 discounted opportunities for dividend growth investors
- DuPont’s Electronics Spinoff: The Start of Something Big
- What Do S&P 500 Stocks Tell Investors About the Market?
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.